FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898047456> ?p ?o ?g. }

• W2898047456 endingPage "243" @default.
• W2898047456 startingPage "235" @default.
• W2898047456 abstract "Few studies have examined chemotherapy-induced peripheral neuropathy (CIPN) following the administration of eribulin as first- or second-line therapy in patients with breast cancer. We therefore assessed CIPN incidence by severity and risk factors for CIPN in patients treated with eribulin for HER2-negative inoperable or recurrent breast cancer, regardless of line therapy status.This multicenter, prospective, post-marketing observational study enrolled patients from September 2014 in Japan and followed them for 2 years. For this interim analysis, the data cut-off point was in November 2017. CIPN severity was assessed based on the Japanese version of the Common Terminology Criteria for Adverse Events, version 4.0.Among 634 patients included in the safety analysis, 374 patients did not have existing CIPN at baseline. CIPN was observed in 105 patients (28.1%), including 67 (17.9%), 34 (9.1%), and 4 (1.1%) patients with grade 1, 2, and 3 severity, respectively. Of the 105 patients, 85.7% patients continued, 7.6% reduced, interrupted or postponed, and 6.7% discontinued eribulin. The median time (min‒max) from baseline to CIPN onset was 60 (3‒337) days. Multivariate logistic regression identified a significant association between CIPN and hemoglobin level at baseline, starting dose of eribulin, and history of radiotherapy.Our findings indicate that, with respect to CIPN, eribulin is well-tolerated, as approximately one-quarter of patients developed CIPN, most cases were grade 1 or 2, and the majority of patients continued eribulin after CIPN onset." @default.
• W2898047456 created "2018-10-26" @default.
• W2898047456 creator A5012322249 @default.
• W2898047456 creator A5043470961 @default.
• W2898047456 creator A5085436946 @default.
• W2898047456 date "2018-10-15" @default.
• W2898047456 modified "2023-10-16" @default.
• W2898047456 title "Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study" @default.
• W2898047456 cites W1952760452 @default.
• W2898047456 cites W1977623079 @default.
• W2898047456 cites W2017807909 @default.
• W2898047456 cites W2024995064 @default.
• W2898047456 cites W2036139631 @default.
• W2898047456 cites W2051043236 @default.
• W2898047456 cites W2077717033 @default.
• W2898047456 cites W2079378158 @default.
• W2898047456 cites W2088110780 @default.
• W2898047456 cites W2092211307 @default.
• W2898047456 cites W2099210388 @default.
• W2898047456 cites W2101979288 @default.
• W2898047456 cites W2114458368 @default.
• W2898047456 cites W2127152525 @default.
• W2898047456 cites W2137545466 @default.
• W2898047456 cites W2143341124 @default.
• W2898047456 cites W2149603226 @default.
• W2898047456 cites W2151194781 @default.
• W2898047456 cites W2152082143 @default.
• W2898047456 cites W2333417235 @default.
• W2898047456 cites W2336327324 @default.
• W2898047456 cites W2343566398 @default.
• W2898047456 cites W2387959609 @default.
• W2898047456 cites W2471488931 @default.
• W2898047456 cites W2484700777 @default.
• W2898047456 cites W2493266198 @default.
• W2898047456 cites W2541724108 @default.
• W2898047456 cites W2592985951 @default.
• W2898047456 cites W2604560583 @default.
• W2898047456 cites W2724602822 @default.
• W2898047456 cites W2754655829 @default.
• W2898047456 cites W2772084872 @default.
• W2898047456 cites W2775770894 @default.
• W2898047456 cites W2966291742 @default.
• W2898047456 doi "https://doi.org/10.1007/s12282-018-0919-8" @default.
• W2898047456 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6394617" @default.
• W2898047456 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30324551" @default.
• W2898047456 hasPublicationYear "2018" @default.
• W2898047456 type Work @default.
• W2898047456 sameAs 2898047456 @default.
• W2898047456 citedByCount "11" @default.
• W2898047456 countsByYear W28980474562019 @default.
• W2898047456 countsByYear W28980474562020 @default.
• W2898047456 countsByYear W28980474562021 @default.
• W2898047456 countsByYear W28980474562022 @default.
• W2898047456 countsByYear W28980474562023 @default.
• W2898047456 crossrefType "journal-article" @default.
• W2898047456 hasAuthorship W2898047456A5012322249 @default.
• W2898047456 hasAuthorship W2898047456A5043470961 @default.
• W2898047456 hasAuthorship W2898047456A5085436946 @default.
• W2898047456 hasBestOaLocation W28980474561 @default.
• W2898047456 hasConcept C121608353 @default.
• W2898047456 hasConcept C126322002 @default.
• W2898047456 hasConcept C134018914 @default.
• W2898047456 hasConcept C141071460 @default.
• W2898047456 hasConcept C143998085 @default.
• W2898047456 hasConcept C197934379 @default.
• W2898047456 hasConcept C23131810 @default.
• W2898047456 hasConcept C2775930923 @default.
• W2898047456 hasConcept C2776387010 @default.
• W2898047456 hasConcept C2777793932 @default.
• W2898047456 hasConcept C2779289229 @default.
• W2898047456 hasConcept C2779901536 @default.
• W2898047456 hasConcept C530470458 @default.
• W2898047456 hasConcept C535046627 @default.
• W2898047456 hasConcept C555293320 @default.
• W2898047456 hasConcept C61943457 @default.
• W2898047456 hasConcept C71924100 @default.
• W2898047456 hasConceptScore W2898047456C121608353 @default.
• W2898047456 hasConceptScore W2898047456C126322002 @default.
• W2898047456 hasConceptScore W2898047456C134018914 @default.
• W2898047456 hasConceptScore W2898047456C141071460 @default.
• W2898047456 hasConceptScore W2898047456C143998085 @default.
• W2898047456 hasConceptScore W2898047456C197934379 @default.
• W2898047456 hasConceptScore W2898047456C23131810 @default.
• W2898047456 hasConceptScore W2898047456C2775930923 @default.
• W2898047456 hasConceptScore W2898047456C2776387010 @default.
• W2898047456 hasConceptScore W2898047456C2777793932 @default.
• W2898047456 hasConceptScore W2898047456C2779289229 @default.
• W2898047456 hasConceptScore W2898047456C2779901536 @default.
• W2898047456 hasConceptScore W2898047456C530470458 @default.
• W2898047456 hasConceptScore W2898047456C535046627 @default.
• W2898047456 hasConceptScore W2898047456C555293320 @default.
• W2898047456 hasConceptScore W2898047456C61943457 @default.
• W2898047456 hasConceptScore W2898047456C71924100 @default.
• W2898047456 hasFunder F4320322148 @default.
• W2898047456 hasIssue "2" @default.
• W2898047456 hasLocation W28980474561 @default.
• W2898047456 hasLocation W28980474562 @default.
• W2898047456 hasLocation W28980474563 @default.

• next